Observational Study of Serum Biomarkers in Multiple Sclerosis Patients
This observational study aimed to evaluate Serum Neurofilament Light Chain and GFAP levels in patients with evolving versus stable disease across a planned enrollment of 1150 participants over various follow-up durations. No results have been posted, so we cannot assess the findings or endpoints.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- No results yet
- Outcome
- Not reported
Why it matters
Understanding variations in serum biomarkers like Neurofilament Light Chain and GFAP may provide insights into MS disease progression and stability, potentially informing future clinical assessments.
What this does not prove
The study has no results published, making it impossible to draw conclusions at this time.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 1150 · planned enrolment
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- people; ages from 15 Years; sex All
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Serum Neurofilament Light Chain; GFAP
- Safety
- Not reported
Original sources
Supporting passages (13)
study phaseStudy type: Observational
study designStudy type: Observational
subjectsParticipants: people; ages from 15 Years; sex All
sample sizeEnrollment: 1150 participants (estimated)
interventionInterventions: Blood sample
primary endpointPrimary endpoints: Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease; GFAP level in patients with evolving disease compared to those with stable disease
follow upFollow-up: Inclusion; 6 months; 12 months; 18 months; 2 years; 3 years; 4 years; 5 years; 6 years; 1 year; 3 year; 4 year; 5 year; 6 year; 2 year; Relapse (measured up to 2 years); EDSS progression (measured up to 2 years); Active MRI (measured up to 2 years)
limitationsNo results are posted. Planned enrolment and endpoints are not findings.
populationThe study population is composed of consecutive patients over 15 years of age, of both sexes, recruited during consultations for a CIS, RRMS or progressive MS at the Neurology department of 30 OFSEP centres and of Nîmes and Nantes University Hospitals.
biomarkersConditions: Multiple Sclerosis
findingsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
peer reviewedTrial registry record.
sample size basisEnrollment: 1150 participants (estimated)
AI assessment, not yet reviewed by a person · version 3 · Community votes are separate from evidence review.